Hartmann, Sylvia
Yasmeen, Summaira http://orcid.org/0000-0001-5470-2081
Jacobs, Benjamin M. http://orcid.org/0000-0002-6023-6010
Denaxas, Spiros
Pirmohamed, Munir http://orcid.org/0000-0002-7534-7266
Gamazon, Eric R. http://orcid.org/0000-0003-4204-8734
Caulfield, Mark J. http://orcid.org/0000-0001-9295-3594
Hemingway, Harry http://orcid.org/0000-0003-2279-0624
Pietzner, Maik http://orcid.org/0000-0003-3437-9963
Langenberg, Claudia http://orcid.org/0000-0002-5017-7344
,
Article History
Received: 6 January 2023
Accepted: 21 September 2023
First Online: 12 October 2023
Competing interests
: Mu. P. has received partnership funding for the following: MRC Clinical Pharmacology Training Scheme (co-funded by MRC and Roche, UCB, Eli Lilly, and Novartis); and a Ph.D. studentship jointly funded by EPSRC and Astra Zeneca. Mu. P. also has unrestricted educational grant support for the UK Pharmacogenetics and Stratified Medicine Network from Bristol-Myers Squibb. Mu. P. has developed an HLA genotyping panel with MC Diagnostics, but does not benefit financially from this. He is part of the IMI Consortium ARDAT (ExternalRef removed). None of the funding outlined above is related to the current paper. None of the other authors have competing interests.